Free Newsletter
Millipore "worth every Euro," says Merck CEO Kley
Merck KGaA CEO Karl-Ludwig Kley says following the late February announcement of the company's acquisition of biotech supplier Millipore, he was asked more than once if the $6 billion price was too high. "I have a clear answer: No, Millipore is worth every euro," he says, as quoted in BusinessWeek. He adds the takeover "will transform" Merck's life science chemicals division. Article
Paid Research Reports
- Trends in mHealth and Telemedicine
- The Global Aesthetic Dermatology Market Outlook
- Future Directions in Regenerative Medicine
- Pipeline Insight: Insulin Antidiabetics – Novel analogs show promise as alternative delivery methods prove less attractive
- Pipeline Insight: Non-insulin Antidiabetics - Rise of the weight-reducers: Once-weekly GLP-1 agonists and novel SGLT-2 inhibitor
- Forecast Insight: Antidiabetics - Diabetes market growth driven by epidemiological trends and rich pipeline
SHARE
WITH: